Related Experiment Video

Updated: Apr 5, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.7K

Current and future treatment strategies for iron overload cardiomyopathy

Suwakon Wongjaikam1, Sirinart Kumfu1, Siriporn C Chattipakorn2

  • 1Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, Thailand.

European Journal of Pharmacology
|August 21, 2015
PubMed

Insights

Combined iron chelators and antioxidants show promise in treating iron overload cardiomyopathy in transfusion-dependent thalassemia (TDT) patients. These therapies may prevent cardiac dysfunction, offering new strategies for TDT patient care.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Iron overload cardiomyopathy is a primary cause of mortality in transfusion-dependent thalassemia (TDT).
  • Accumulation of iron in the heart leads to significant cardiac dysfunction and failure.
  • Current management strategies require optimization for TDT patients.

Purpose of the Study:

  • To review the therapeutic efficacy of combined iron chelators and antioxidants in managing iron overload cardiomyopathy.
  • To explore the impact of these combined therapies on myocardial iron deposition and cardiac function.
  • To provide insights into future therapeutic strategies for preventing cardiomyopathy in TDT.

Main Methods:

  • Comprehensive review of basic and clinical research reports.
  • Analysis of studies investigating combined iron chelator therapy.
  • Evaluation of studies combining iron chelators with antioxidant agents.

Main Results:

  • Combined iron chelators effectively reduce myocardial iron burden.
  • Combination therapy with antioxidants further attenuates cardiac dysfunction in TDT patients.
  • Evidence supports the beneficial effects of these combined treatments on cardiac health.

Conclusions:

  • Combined iron chelators, with or without antioxidants, offer a promising therapeutic approach for TDT patients.
  • These strategies can prevent or mitigate cardiac dysfunction caused by iron overload.
  • Future research should focus on optimizing these combined therapies for improved TDT patient outcomes.

Keywords:
AntioxidantDeferasiroxDeferiproneDeferoxamineIron chelatorIron overload cardiomyopathy

More Related Videos

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

12.3K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.6K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
656
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
772
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
583
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
732
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
546
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K